Spyre Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2014 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Spyre Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2014 to 2024.
  • Spyre Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$61.3M, a 33.4% decline year-over-year.
  • Spyre Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$209M, a 13.9% increase year-over-year.
  • Spyre Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$209M, a 13.9% increase from 2023.
  • Spyre Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$242M, a 186% decline from 2022.
  • Spyre Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$84.8M, a 29.1% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$209M +$33.7M +13.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 -$242M -$158M -186% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 -$84.8M -$19.1M -29.1% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 -$65.6M +$15.8M +19.4% Jan 1, 2021 Dec 31, 2021 10-K/A 2024-11-18
2020 -$81.5M -$1.15M -1.43% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 -$80.3M -$34.9M -76.7% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-08
2018 -$45.5M -$17.8M -64.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-18
2017 -$27.7M -$5.77M -26.3% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-24
2016 -$21.9M -$10.6M -93.6% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-07
2015 -$11.3M -$2.41M -27.1% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-13
2014 -$8.9M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.